Home  /  Resource Library  /  Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off Treatment Follow up From the Randomized CLL14 Study

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off Treatment Follow up From the Randomized CLL14 Study

Study compared minimal residual disease in patients with chronic lymphocytic leukemia treated with venetoclax combined with obinutuzumab or chlorambucil combined with obinutuzumab.